QuidelOrtho (NASDAQ:QDEL) Receives New Coverage from Analysts at Citigroup

Citigroup assumed coverage on shares of QuidelOrtho (NASDAQ:QDELGet Rating) in a research report released on Monday, Marketbeat Ratings reports. The firm issued a neutral rating and a $90.00 price target on the stock.

Other equities analysts also recently issued research reports about the stock. StockNews.com downgraded shares of QuidelOrtho from a buy rating to a hold rating in a report on Monday, August 15th. JPMorgan Chase & Co. assumed coverage on shares of QuidelOrtho in a report on Friday, June 17th. They issued a neutral rating on the stock. Finally, UBS Group assumed coverage on shares of QuidelOrtho in a report on Wednesday, July 20th. They issued a sell rating and a $86.00 price target on the stock. One analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, QuidelOrtho presently has a consensus rating of Hold and an average target price of $96.50.

QuidelOrtho Trading Down 2.6 %

Shares of NASDAQ:QDEL opened at $73.56 on Monday. The stock has a 50 day moving average of $88.96 and a 200 day moving average of $98.36. The company has a market cap of $4.93 billion, a PE ratio of 3.12 and a beta of 0.12. The company has a current ratio of 1.73, a quick ratio of 1.12 and a debt-to-equity ratio of 0.51. QuidelOrtho has a 12-month low of $73.29 and a 12-month high of $180.06.

Institutional Trading of QuidelOrtho

Large investors have recently made changes to their positions in the business. Western Pacific Wealth Management LP bought a new stake in shares of QuidelOrtho in the 4th quarter worth about $26,000. First Horizon Advisors Inc. increased its holdings in shares of QuidelOrtho by 2,580.0% in the 2nd quarter. First Horizon Advisors Inc. now owns 268 shares of the company’s stock worth $26,000 after buying an additional 258 shares during the last quarter. Parkside Financial Bank & Trust grew its holdings in QuidelOrtho by 177.3% during the 2nd quarter. Parkside Financial Bank & Trust now owns 305 shares of the company’s stock valued at $30,000 after purchasing an additional 195 shares during the last quarter. Exane Derivatives grew its holdings in QuidelOrtho by 4,883.3% during the 1st quarter. Exane Derivatives now owns 299 shares of the company’s stock valued at $34,000 after purchasing an additional 293 shares during the last quarter. Finally, New Century Advisors LLC grew its holdings in QuidelOrtho by 52.6% during the 2nd quarter. New Century Advisors LLC now owns 351 shares of the company’s stock valued at $34,000 after purchasing an additional 121 shares during the last quarter. 87.20% of the stock is currently owned by institutional investors.

About QuidelOrtho

(Get Rating)

QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.

Read More

Receive News & Ratings for QuidelOrtho Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for QuidelOrtho and related companies with MarketBeat.com's FREE daily email newsletter.